1 follower
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.
Charles McDermott
Thermo Fisher Scientific
180 followers
Gilead Sciences
136 followers
Biogen
123 followers
Regeneron
104 followers
Vertex Pharmaceuticals
66 followers
Agilent Technologies
72 followers
Verily Life Sciences
38 followers
bluebird bio
40 followers
Ionis Pharmaceuticals
29 followers
Kura Oncology
20 followers
Charles River Laboratories
14 followers
Explore companies